Julie Bolcaen
Overview
Explore the profile of Julie Bolcaen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
214
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mendes F, Terry S, Spiegelberg D, Cornelissen B, Bolcaen J, Nonnekens J
Eur J Nucl Med Mol Imaging
. 2025 Feb;
PMID: 40014072
The growing interest and investments in targeted radionuclide therapy (TRT) have expanded research efforts across preclinical and clinical domains. Researchers from diverse fields, including nuclear medicine, radiochemistry, radiopharmacy, radiotherapy, biology,...
2.
Bolcaen J, Combrink N, Spoormans K, More S, Vandevoorde C, Fisher R, et al.
Front Nucl Med
. 2024 Oct;
3:1209823.
PMID: 39355046
Personalised dosimetry based on molecular imaging is a field that has grown exponentially in the last decade due to the increasing success of Radioligand Therapy (RLT). Despite advances in imaging-based...
3.
Bolcaen J, Gizawy M, Terry S, Paulo A, Cornelissen B, Korde A, et al.
J Nucl Med
. 2023 Aug;
64(9):1344-1351.
PMID: 37591544
Auger electron (AE) radiopharmaceutical therapy (RPT) may have the same therapeutic efficacy as α-particles for oncologic small disease, with lower risks of normal-tissue toxicity. The seeds of using AE emitters...
4.
Jansen van Vuuren A, Bolcaen J, Engelbrecht M, Burger W, de Kock M, Durante M, et al.
Animals (Basel)
. 2023 Jul;
13(14).
PMID: 37508130
Following population declines of the African savanna elephant () across the African continent, the establishment of primary cell lines of endangered wildlife species is paramount for the preservation of their...
5.
Everix L, Seane E, Ebenhan T, Goethals I, Bolcaen J
Pharmaceuticals (Basel)
. 2023 Jun;
16(2).
PMID: 37259375
Despite recent advances in multimodality therapy for glioblastoma (GB) incorporating surgery, radiotherapy, chemotherapy and targeted therapy, the overall prognosis remains poor. One of the interesting targets for GB therapy is...
6.
Recombinant Endostatin as a Potential Radiosensitizer in the Treatment of Non-Small Cell Lung Cancer
Cunningham C, Bolcaen J, Bisio A, Genis A, Strijdom H, Vandevoorde C
Pharmaceuticals (Basel)
. 2023 Jun;
16(2).
PMID: 37259367
Non-small cell lung cancer (NSCLC) is the most prevalent type of lung cancer, which is the leading cause of cancer-related deaths worldwide. Over the past decades, tumour angiogenesis has been...
7.
Everix L, Nair S, Driver C, Goethals I, Sathekge M, Ebenhan T, et al.
Cancers (Basel)
. 2022 Apr;
14(7).
PMID: 35406593
Despite numerous innovative treatment strategies, the treatment of glioblastoma (GB) remains challenging. With the current state-of-the-art therapy, most GB patients succumb after about a year. In the evolution of personalized...
8.
Nair S, Cairncross S, Miles X, Engelbrecht M, du Plessis P, Bolcaen J, et al.
J Vis Exp
. 2022 Jan;
(178).
PMID: 35001906
Ionizing radiation is a potent inducer of DNA damage and a well-documented carcinogen. Biological dosimetry comprises the detection of biological effects induced by exposure to ionizing radiation to make an...
9.
Engelbrecht M, Ndimba R, de Kock M, Miles X, Nair S, Fisher R, et al.
Sci Rep
. 2021 Oct;
11(1):20854.
PMID: 34675263
The radiosensitivity of haematopoietic stem and progenitor cells (HSPCs) to neutron radiation remains largely underexplored, notwithstanding their potential role as target cells for radiation-induced leukemogenesis. New insights are required for...
10.
Bolcaen J, Kleynhans J, Nair S, Verhoeven J, Goethals I, Sathekge M, et al.
Theranostics
. 2021 Aug;
11(16):7911-7947.
PMID: 34335972
Despite numerous clinical trials and pre-clinical developments, the treatment of glioblastoma (GB) remains a challenge. The current survival rate of GB averages one year, even with an optimal standard of...